OAKVILLE, ON, April 20 /CNW/ - Pharmaceutical Development Corporation
(www.pharmdevcorp.com) today announced that Diane Kalina, Co-founder and
President, will be presenting at Biofinance 2007 in Toronto. Ms. Kalina's
presentation will take place on Thursday, April 26th at 10:30 am at the
Toronto Marriott Eaton Centre.
About Pharmaceutical Development Corporation
Pharmaceutical Development Corporation (PDC) is a private Canadian
biopharmaceutical development company which in-licenses, develops and obtains
financing/partnerships for early stage opportunities in areas of unmet medical
need and for therapeutic areas in which PDC possesses in-house clinical
development expertise. Initially, the company is focusing on the women's
health areas of preterm labour and primary dysmenorrhea.
PDC's lead molecule, PDC31 (formerly THG113.31) is a peptide which has
shown efficacy in vitro and in animal models of preterm labour. This peptide
is one of a family of peptides and peptidomimetics in-licensed from
Theratechnologies. PDC plans to develop an injectable formulation of PDC31 as
a treatment for acute treatment of pregnant women with preterm labour, and a
topical formulation of the same peptide for use in women with primary
dysmenorrhea.
For further information: Diane Kalina, President, (905) 829-9770 ext
223; Patricia Griffin, Executive Vice President, (416) 698-0011
